FDA Launches Emergency Program to Expedite the Development of COVID-19 Treatments
Shots:
- The US FDA has launched Coronavirus Treatment Acceleration Program (CTAP) to expedite the development of safe and effective drugs targeting COVID-19. FDA’s CTAP is a tool to bring new therapies to the patients as soon as possible
- Under CTAP- FDA is redeploying staff and streamlining processes to hasten the reviews of clinical trial protocols and single-patient expanded-access requests
- FDA unveiled that 10 therapeutic agents are in active trials and 15 agents in the planning stages. The FDA highlights some treatments that are currently being investigated for COVID-19 including Gilead’s remdesivir- Roche’s Actemra (tocilizumab) and Sanofi & Regeneron’s Kevzara (sarilumab)
Source 1- Source 2 to read full press release/ article | Ref: Eyewire- FDA | Image: FDA
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com